Annovis Bio, Inc.
ANVS
$2.60
-$0.10-3.70%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 24.79% | 7.40% | 3.32% | -23.56% | -33.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -41.30% | -40.72% | -28.28% | 20.18% | 41.84% |
| Operating Income | 41.30% | 40.72% | 28.28% | -20.18% | -41.84% |
| Income Before Tax | 38.86% | 56.25% | 1.86% | -28.67% | -59.34% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 38.86% | 56.25% | 1.86% | -28.67% | -59.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 38.86% | 56.25% | 1.86% | -28.67% | -59.34% |
| EBIT | 41.30% | 40.72% | 28.28% | -20.18% | -41.84% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 57.10% | 68.27% | 22.27% | -10.72% | -38.01% |
| Normalized Basic EPS | 57.10% | 68.27% | 22.27% | -10.72% | -38.01% |
| EPS Diluted | 60.86% | 57.34% | 9.57% | -26.06% | -55.04% |
| Normalized Diluted EPS | 57.09% | 68.30% | 22.31% | -10.68% | -37.96% |
| Average Basic Shares Outstanding | 44.13% | 34.97% | 30.62% | 22.09% | 17.83% |
| Average Diluted Shares Outstanding | 43.39% | 35.53% | 31.21% | 22.69% | 18.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |